Index

а	 Federal Technology Transfer Act 48
academic sector 40, 131ff.	– Japan's 51, 72
Access and Benefit Sharing (ABS) 157f.	– system 47
Administrative Authority for Patent Affairs	– type rights 53, 57
(AAPA) 84f., 87	– US 11, 36ff.
African Agricultural Technology Foundation	Belgium 50
(AATF) 202	benchmarks 136, 188
Agreement on Subsidies and Countervailing	bench-top experiments 39
Measures 201	biodiversity 146f., 157f.
agricultural biotechnology 128f., 133f.,	bio-economy 127, 133, 137ff.
138f., 202ff.	bio-fuels 123, 126, 129
- budget 138f.	biological diversity, see biodiversity
- chemicals 123	biologics, see therapeutic biotechnology
- communication 128f., 133	products
- coordination 128f., 131f.	bio-piracy 158
- diversification 137	biosafety 203
 dowstream switching costs 133f. 	biotechnology
driven deregulation process 130	– agricultural 123ff.
- leaders 132f., 135, 137	– financing 188ff.
– self-control 130	– in-house 15
– self-regulation 130	 international framework 195ff.
- specialization 137	– Latin-America 106ff.
- value chain 128f., 133f.	- sector 17, 39
Alma Ata Declaration 173	Biotechnology Trust of Africa 202f.
ancillary rights 25	BMBF (Bundesministerium für Bildung und
Argentina	Forschung) 105
- biotechnology 109ff.	bottom-line monetary improvements 149
- INTA 118	bottom-up policies 50
– RELMÓ 118	Brazil 54, 57, 101ff.
 technology transfer, see Latin-America 	– BIOTA/FAPESP 108
Association of University Technology	– biotechnology 107ff.
Managers (AUTM) 40, 48, 52, 163,	– CNPq 107f.
166	– EMBRPA 115
Australia 54	- FINEP 108
Austria 50	– FIOCRUZ 109, 115f.
authorization holder 145	– PASNI 116
	– patent numbers 114
b	 technology transfer, see Latin-America
basic research activities 52	Brazilian Agricultural Research Corporation
Bayh–Dole Act	202

Technology Transfer in Biotechnology. A Global Perspective.
Edited by Prabuddha Ganguli, Rita Khanna, and Ben Prickril
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 978-3-527-31645-8

breeding 124f. confidential endorsement 18 - advanced breeding techniques 125 confidentiality - conventional 125f. - agreement 18, 148 - clauses 34 - marker-assisted 124f., 203 - contract 19 plant-breeding process 124 Burrill Biotech Select Index 188 - obligation 18f. conflict of interest 168f. c Congressional Joint Economic Committee Canada 51f., 54, 118 contract CAP (Common Agricultural Poicies) 139 Centre National de le Recherche Scientifique - assignment 25 (CNRS) 23 - circulation 32 - duration 34 Chile - founder 22ff. biotechnology 111f. CORFO 111 - license 25, 31 - technology transfer, see Latin-America - main license 24 China 54, 79ff. - public bodies 22 Anti-Unfair Competition Law 88f. - R&D 25, 30 - sublicense 24 - biotechnology 81f. - cross-board technology transfer 79ff. - Technology Transfer Agreement (TTA) government policy 82f. 24ff. - transfer 20 Import and Export Regulations 90ff. - industry dissemination 80f. contractual - MOFCOM (Ministry of Commerce) 80, - negotiations 15, 17ff. - networks 16 - MOFTEC (Ministry of Foreign Trade and - pre- 17ff. Economic Cooperation) 80, 92 - protection 88ff. - patent applications 84ff. technologies 16 patent law 86 Convention on Biological Diversity 146, 157 Cooperative Research and Technology - patent protection 84ff. Supreme Court Interpretations 90, 95, Agreements (CRADAs) 37f., 42 Cooperative Research and Technology - taxation 98 Enhancement Act (CREATE ACT) 8 technology contract 95ff. Court of Appeal 23, 37 - technology export 82, 90ff. Court of Cassation 23 Creative Commons 11 - technology import 80f., 90ff. - technology transfer 90ff. trade secret protection 88ff. commercial GMO 126, 134, 138 - first generation 124 claims - DNA-based 6f. - green 139 - reach-through 44, 147, 151, 153, 155 health-promoting products 139 clauses 18 - HIT-carrying 126, 131f., 138 - antistacking 32f. - innovative 124ff. - financial 29f. - global crop protection market 126 - new functionalities 127, 137, 139 flexibility 34 – non-use 19 - new top 138 clinical - renewable products 139 - preclinical trials 29 cross-board technology transfer 79ff. – trials 145 company d database law 16 - major 16f., 29 Denmark 50, 143, 204 private 16f., 49 - start-up 15f., 124, 128, 131ff. Department of Defense 41 competition, see law deregulation processes 130

developing countries 46, 113, 197ff. diligence 38, 43 – due 38, 148 diclosure 54f. dissemination 54, 80f., 197 domains 26f. Drugs for Neglected Diseases Initiative 174	g Gates Foundation's Grand Challenges in Global Health Program 176 Gene - mapping 124related innovations 46splicing technology 39 genetic inventions 9f. genetically modified organism (GMO) 125f.		
e	- crop 126		
emerging-market countries 46	– non-GMO solutions 125		
entrepreneurial	– technology in Europe 127		
- ferment 165f.	General Agreement on Tariffs and Trade		
- sector 39	(GATT) 47, 145, 179		
entrepreneurship 164ff.	German Employed Inventor's Act 50		
ethical concerns 9, 156	Germany 50, 54, 143		
European Block Exemption for Technology Licenses 143	germplasm 125, 135 Ghana 57		
European Commission Regulation 27, 31, 49, 144	Global Health Networks 173ff. global transformation 185ff.		
European Directive on Biotechnological Invention 204f.	Government Accounting Office 41 Government		
European Free Trade Association 118	– agencies 40		
European Patent Convention 67	– control process 130		
European Patent Office 54	– -funded patents 42		
evergreening 55	funded research 38f., 52, 144		
evolutionary technological advance 55	funded technology 36		
exclusivity 20, 22, 37f., 56f., 145, 148	- funding 41, 144		
- co-exclusive basis 26f.	- inspection process 130		
- market 145	- invetsigators 37		
- period 145	- laboratories 36f., 39		
exemption regulation 31, 145 EXIST 50	- sanctioning process 130		
expressed sequence tags (EST), see patenting	grace period 54f. grant 36ff.		
expressed sequence tags (EST), see pateriting	back 143, 149, 157		
f	back 1+3, 1+7, 137		
Federal technology Transfer Act 104	h		
Finland 50	Hatch–Waxman Act 145		
first-to-file 53f.	health-care system 11, 187f.		
first-to-invent 53	herbicide		
Food and Agriculture Organization (FAO) 202	- resistant 204 - tolerance 123f., 126		
Food and Drug Administration (FDA) 4, 29, 40, 145, 178f., 187	HIT (high impact traits) 125f., 128ff. – costs 133f.		
for-profit 40, 153	- drop out rates 133		
- not- 153	Human Genome Project 11, 186		
– research 44			
founder contracts, see contracts	i		
Framework Program for Research and	improvements 30f., 34		
Technological Development 144	incentive 38f., 44, 56f., 198		
– FP6 144, 156f.	– capital investment 56		
– FP7 157	incremental innovation 55		
France 50, 54, 57, 114	India 56, 159		
freedom-to-operate 142	Initial Public Offering (IPO) market 191ff.		

injunction 43	– policies 70ff.
innovation	– technology import 80
- capacity 200	- Technology Licensing Organization (TLO)
– capture 141	63, 71,
- commercialization 200	 university-industry relationships 59ff.
- expenses 142	university industry relationships 3511.
- leading-edge 200	k
open innovation platforms 123, 128,	know-how 22, 26ff.
131f., 137f.	– proprietary 144
- research-based 155	
	– protection 16
input traits, see traits	knowledge
insect	based bio-economy 127
- control 123f.	– economy 162
- resistance 126	– sequestration 175
Institutional Patent Agreements (IPAs)	,
36	
Intellectual Property Rights (IPR) 1ff. – dangers 147f.	large molecules, <i>see</i> therapeutic biotechnology products
– frameworks 9	Latin-America 101ff.
- information 8	 academia-industry cooperation 101ff.
– Japan 59ff.	- incentives 103
- lawsuit 148	- investments in biotechnology 106ff.
- ownership 11, 51, 168	 policies for marketing biotechnological
- protection 4, 9, 197	knowledge 112ff.
- system 9	law
- warehousing 11	– anti-trust 142
interference 53	- competition 142f., 154
International Center for Genetic Engineer-	Least Developed Countries (LDCs) 56, 196ff
ing and Biotechnology (ICGEB) 205ff.	legal frameworks 142
International Code of Conduct on Transfer	legislation 38, 162, 198
of Technology 196	Letter of Intent 20
inventor remuneration 144	license
ISI Deluxe 107	– automatic 152
Italy 51	- call-back 152
Italy 31	
j	- compulsory 57, 146, 198 - exclusive 22, 31, 38, 44, 151f., 162f., 180
Japan 51, 54, 56	
	- negotiations 11, 168
- Biotechnology Strategy Council 64f.	– non-exclusive 22, 151, 156, 162, 180 – number 38
- IP management 59ff.	
- IP policies 61ff.	- option for 152
- IP promotion 61ff.	licensee 24, 28, 31, 33, 37f., 41, 43, 149
- IP-related projects 59, 63ff.	liscensing
- IP Strategy Council 60	- agreement 198
- medical patentability 65ff.	- competition 141f.
– METI (Ministry of Economy, Trade and	- exclusive 37f., 40
Industry) 71	- fees 131
- MEXT (Ministry of Education, Culture,	- finality licensing agreement 11
Sports, Science and Technology) 71f.,	- genetic research tools 155
74, 76, 78	- in- 141f., 145, 149ff.
- Outline of IP Strategy 68	– income 167f.
 patent application control 76 	– offices 143
– Patent Office 64	– open-source 11
patent protection 68f.	– out- 143, 148ff.

– payment 143	Norway 50		
– practices 9f., 148ff.	novelty standard 54		
- transactions 148, 155f.	nutraceuticals 123, 126		
licensors 28			
- control 11	o		
– second-rank 24	obligations 168		
life sciences sector 15f., 25, 32, 34	Office of General Council 39		
litigation proceedings 33, 144, 150, 205	Office of Technology Management (OTM)		
living material 21, 26	71		
,	Office of Technology Transfer (OTT) 39,		
m	71		
march-in 37, 42f., 57	Organization for Economic Cooperation		
Material Transfer Agreements (MTA) 21,	and Development (OECD) 9, 46, 142		
142, 150f.	– Effects of Patents in Blocking Research		
Max Planck Society's (MPS) technology	and Commercial Developments 155		
transfer division 50	- Guidelines for the Licensing of Genetic		
medical practice-related technology 68	Inventions 142, 147, 153, 155		
Memorandum of Understanding (MOU)	- report 9f.		
20f., 25, 40f.	ownership 21f.		
mergers 190	– international 51		
Metabolic pathways 126	– joint 22, 25		
Mexico 54, 118	- of the rights 25		
milestones 28f.	– patent 23, 50		
– payment 28, 150	- transfer 21		
- performance 38, 43	Oxford Genetics Knowledge Park (OGKP)		
Millennium Development Goals (MDGs)	()		
173f.	p		
monopoly 155	Paris Convention 112, 198		
– patent 55	partnering transactions 190f.		
– virtual 10f.	Patent and Trademark Office (PTO) 5f., 9,		
	36, 114f., 118		
n	patent		
NASDAQ 188, 190	– allowance 5		
National Institute of Health (NIH) 21,	- application 11, 43, 52ff.		
35ff.	– assignee 42		
– extramural program 35f., 44	- blockbuster 163		
funded research 41f., 153	- blocking 155		
– global efforts 45f.	- breadth 4, 6		
- intramural program 35f., 44, 49	– claims 4ff.		
- licensed technologies 38, 40	– eligibility 56		
- Research Tools Guidelines 40, 46	– examination 67, 70		
National Science Foundation (NSF) 102,	exemption regulation 31, 145		
177	- filing 11, 15, 23, 53ff.		
Netherlands 203f.	– freedom licences 150		
New Molecular Entities (NME) 145	– gene-related 11		
Non-Disclosure Agreements (NDA) 11,	– granting 10		
17ff.	harmonization 55		
Non-Governmental Organizations (NGOs)	- holder 3, 5, 10, 156, 180, 205		
46	- infringement 43f., 84, 86ff.		
non-profit	patent law 3, 144		
– foundations 102	- Chineses 86		
- institutions 37, 40, 45, 162	– European 54		
- researchers 41, 44	– US 54, 67		

216	Index			
-	patent	public		
	- litigation costs 33, 144, 150	- bodies 16, 19, 22, 29f., 178		
	– non-infringing 148	- engagement 10		
	– off- 159	- funding recipient 50		
	– offices 9f., 54	- health 42, 45, 57		
	- policy 37, 42, 44	- safety 42		
	– pools 16, 156	publications 21f., 34, 54, 101		
	– privatization 9	public-private partnerships (PPPs) 8, 11,		
	– proprietor 24f.	48, 123, 130, 175		
	- protection 3, 26, 39f., 53, 55f., 68, 145,	public research bodies 29f., 178		
	149, 152f., 175, 204	public research organizations (PROs) 39f.,		
	– re-examination 5f.	42f., 47ff.		
	– rejection 5	– European 49		
	- specificity 4, 6f., 198	– US 49, 52		
	– strategic 11	publicity funded research Organizations		
	- system 10, 37, 53	46ff.		
	- trolls 16	publish or perish 176		
	– validity 31, 144	punitive damage 43		
	patentability			
	– antibodies 2f.	r		
	- benchmarks 10	rampant bio-piracy, see bio-piracy		
	– Expressed Sequence Tags (EST) 4	raw materials		
	– gene sequences 2f., 6f.	- HIT-derivd 128		
	- guidelines 10	- industrial 123, 128		
	– medical activity 65ff.	reach-through rights 44, 147, 151, 153, 155		
	- research tools 2, 4, 9	reimbursement 40f.		
	- stem cells 5f., 11	research		
	payment 28 – advance 30	exemptions 9f.networks 180f.		
		– new models 175ff.		
	down-payment on signature 29f.PCT (Patent Cooperation Treaty) 114f., 118			
	peer-reviewed 54	Research and Development (R&D) – collaborations 142f., 152f.		
	pharmaceuticals 41, 56, 69	- investments 158ff.		
	plant-based	Research Tools Guidelines, see National		
	- innovations 128	Institute of Health (NIH)		
	– production 137	rights of first refusal 32		
	- speciality products 123, 127f., 137	royalities 11, 16, 26f., 29, 147, 150f., 197		
	plant-made pharmaceuticals 123, 126	- anti-royality stacking clause 150		
	plant sciences 123, 125	bearing licenses 39, 147, 150		
	plant variety	– downstream 153		
	– protection 204	free basis 37, 40, 149, 162, 202		
	- rights 16	– global payment 197		
	Poland 143	- income 38		
	portfolio 38, 141	– rate 29		
	pre-market preparation 129, 134	- reach-through 151, 153, 155		
	Private Investment in Public Equities	– revenue 163		
	(PIPEs) 189, 193	- stacking 32f., 150		
	privatley funded research 11	Russia 50		
	professor's privilege' system 50			
	proof-of-concept 135	S		
	proprietary 144, 148, 154, 156	Science Citation Index (SCI) 103		
	provision 29f.	scientific publications, see publications		
	PTM (Patent and Technology Management)	secrety agreement 17, 19		
	71	seed 125f.		

selfreproduction 26 small business 37, 53, 162	technology utilization 27f. territory 27
Small Business Innovation Research Program 162	therapeutic biotechnology products 141f. top-down policies 50
South Africa 54	trade-off 168
South Korea 80, 105, 118	trade secret protection 88ff.
Spain 50, 105, 204	traits 123, 125ff.
spin-offs 16, 22	– GMO 127
– of innovations 188	- high impact (HITs) 125f., 128ff.
– private sector companies 49	- input 123
spin-out company 52	- licensing 135
stakeholder 10, 40, 128	- stacking 136
start-up	Treaty of Rome 31
– biotechnology 124, 128, 131ff.	Triple Helix 177f.
- cash-craving 136	TRIPS (Trade-Related Aspects of Intellectual
- company 15f.	Property Agreement) 47, 56f., 84, 105,
124, 128f., 164f.	120, 145f., 196ff.
– university 164f.	– compliance cascade 56
statutory conditions 42f.	- conference in Doha 57, 146, 196, 199
Stevenson–Wydler Technology Innovation	two-tier 180
Act 36, 38f., 104, 177	
sublicense 20, 22, 24	и
Supreme Court 39, 145, 154f.	United Kingdom 50f., 54, 105, 158, 178
Sweden 50	United Nations Population Division 141
Swiss 143, 145	Universal Biological Materials Transfer Agreement 40
t	university-industry relationships 48, 50
Taiwan 54, 105	– Japan 59ff.
take it or leave it 143	– Latin-America 114, 118
taxpayer 41	– policies 70ff.
technical protection 200	university-licensed technologies 38, 163
technology	up-fronts 155
– import 79ff.	Uruguay, see Latin-America
– licensed 11	Utility Examination Guideline 5
– platform 2f., 12	utilization phases 28
– pre-existing 152	
– Roundup Ready 204	ν
Technology Transfer Agreement (TTA)	Venezuela 54
21f., 24ff.	venture
Technology Transfer Commercialization	– capital 192f., 200
Act 104	– financing 193
technology transfer 1, 7ff.	Veterans Administration 41
– cross-board 79ff.	
– growth in laboratories 39ff.	W
– in China 90ff.	win/win situation 129f.
– international 46ff.	World Intellectual Property Organization
 international framework 196ff. 	199
– Latin-America 101ff.	World Trade Organization (WTO) 47, 57, 84
– legislation 36	101, 146, 158f., 196f.
– life sciences sector 15, 24	 Trade-Related Aspects of Intellectual
– office 168	Property Agreement, see TRIPS
– policy 9ff.	